Menlo Park, United States
Aether, founded in 2017, is at the forefront of merging AI and Machine Learning with biotech innovation. Positioned as an American pioneer, the company's mission—encapsulated in its slogan, "We're building the post-scarcity future"—hints at its ambitious vision of transforming various industries through novel scientific advances.
Central to Aether Biomachines' achievements is a proprietary Protein Function Model, leveraging an exclusive dataset generated through sophisticated high-throughput screening techniques. This groundbreaking platform has enabled the discovery of seven new classes of proteins. These innovations have significant implications across sectors: from cost-effective metal refining and solving the "forever chemicals" problem, to enhancing pharmaceutical processes and advancing environmental solutions.
The recent $49.00M Series A investment on 15 August 2023, with backing from investors like AMPLIFIER, Unless, Natural Capital, and Good AI Capital, underscores the confidence in Aether's remarkable potential to revolutionize industries with its high-performance AI-derived materials.
